Issues: Vax Specific

Anthrax

Hepatitis B

Hib 

HPV

Influenza

Lyme Disease
Meningococcal

MMR    

Pneumococcal

Polio

Rotavirus

● Smallpox

Tdap/Td

Varicella

Yellow Fever

 

Issues: Misc

Exemptions

Legislation 

New Vax Status

Religion

Thimerosal

 

Vaccine Info

2014 Schedule

ACIP Recs

Components
IOM Reports

● Vax Injury Comp Program
Manufacturer Links

Package Inserts

Reporting AEs

Thimerosal Table

VAERS

VISs

 

Links
 

Search
 

About IVS

Faculty Biographies

Publications

Donations

 

Email IVS

 

Disclaimers & Privacy
 

 

Haemophilus influenzae type B (HiB) VACCINE

  • Menhibrix, a new 4-dose combination vaccine to protect against meningococcal and Hib diseases, has been approved for use in ages 6 weeks to 18 months. Link to FDA News Release (6-14-12)

  • Hiberix, a vaccine against Haemophilus influenzae type b (Hib), has been approved by the US FDA as a booster dose.  The vaccine was approved through an accelerated process to ease the shortage of Hib vaccine in the US. Link to FDA News Release (Aug 19 09)

  • Continued Shortage of Haemophilus influenzae Type b (Hib) Conjugate Vaccines and Potential Implications for Hib Surveillance --- United States, 2008.  MMWR Nov 21 2008:57(46);1252-5. [Dec 08]

    • no increase in disease due to shortage

  • IVS has learned that no samples of the recalled lots were found to be contaminated. [Dec 08]

  • Pentacel, a vaccine for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease caused by Haemophilus influenzae type b for infants and children 6 weeks through 4 years of age (prior to fifth birthday), was approved by the US FDA in June 2008.

This page was last updated on February 12, 2014

2013 Institute for Vaccine Safety